- Previous Close
114.47 - Open
115.05 - Bid 113.76 x 900
- Ask 117.25 x 1100
- Day's Range
113.68 - 115.10 - 52 Week Range
92.19 - 120.92 - Volume
1,004,421 - Avg. Volume
1,193,595 - Market Cap (intraday)
231.132B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
23.27 - EPS (TTM)
4.89 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield 3.78 (3.30%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
117.90
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVS
View MorePerformance Overview: NVS
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVS
View MoreValuation Measures
Market Cap
232.57B
Enterprise Value
253.13B
Trailing P/E
23.41
Forward P/E
14.08
PEG Ratio (5yr expected)
1.74
Price/Sales (ttm)
4.83
Price/Book (mrq)
5.55
Enterprise Value/Revenue
5.18
Enterprise Value/EBITDA
13.34
Financial Highlights
Profitability and Income Statement
Profit Margin
33.11%
Return on Assets (ttm)
8.86%
Return on Equity (ttm)
21.50%
Revenue (ttm)
48.86B
Net Income Avi to Common (ttm)
10.08B
Diluted EPS (ttm)
4.89
Balance Sheet and Cash Flow
Total Cash (mrq)
8.43B
Total Debt/Equity (mrq)
69.18%
Levered Free Cash Flow (ttm)
14.81B
Research Analysis: NVS
View MoreCompany Insights: NVS
NVS does not have Company Insights
Research Reports: NVS
View MoreNovartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 09/03/2024: Global Dividend Investing
Global stocks are gaining, if not at the pace of domestic equities. While the S&P 500 has risen 17% year to date, the EAFA index of large- and mid-cap stocks based in countries other than the U.S. and Canada has gained 9.5%. Over the past five years, the performance gap has been wider, with the S&P 500 advancing 94% compared to a 32% gain in EAFE. But the underperformance has given global stocks a valuation advantage, particularly in the area of dividends. Consider that the EAFE dividend yield of 2.9% is 170 basis points higher than the comparable S&P 500 dividend yield. We think global dividend stocks now offer opportunity, particularly given the endless speculation over the direction of interest rates in the U.S., which has created market-timing headaches for equity income investors, who have endured recent wide swings in prices for rate-sensitive equity in areas such as utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S. interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection of companies that pay dividends, robust industry diversification, and, as we have mentioned, higher yields and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks, each of which has at least a long-term BUY rating from an Argus analyst. Note this list of approximately 25-30 companies offers exposure to eight of the 11 major industrial sectors. The list includes companies from 10 countries.
Novartis Earnings: Despite Solid Results, Increasing Generic Pressure in 2025 Likely to Slow Growth
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
RatingPrice TargetHOLD as Entresto set to lose exclusivity in 2025
Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.
RatingPrice Target